For how we live.
A Quezon City hospital reviewed 20 children admitted with subacute sclerosing panencephalitis over 16 years. A quarter arrived in 2022, and the timing points back to the 2018–2019 measles outbreak.
A modelling study finds South Africa's selective birth-dose policy is efficient per infection averted, but giving every newborn a dose would prevent the most disease and be the most cost-effective overall.
It hangs in the air for up to two hours and infects the great majority of susceptible people it reaches. Less well known: it can erase part of the immune memory a person had already built to other diseases.
The more contagious a disease, the more of a population must be immune to stop it spreading. Measles sets the bar near 95%. It is not one figure but a range that depends on where you are.
Every vaccine does the same job — teach the immune system to recognise a pathogen before it arrives. What differs is how they show it the target: live, inactivated, protein, viral vector, or mRNA.
A registry analysis of Abyan Governorate from 2020 to 2024 puts numbers on a vaccine-preventable disease that returned as immunisation coverage fell — with the heaviest toll among children aged 5 to 9.
An analysis of a decade of surveillance data shows the system leans heavily on hospitals and misses cases in the community — the weakness that lets measles circulate undetected between outbreaks.
A systematic review of the Syrian crisis and infectious disease in Lebanon names overcrowding, poor sanitation and blocked healthcare access — not the presence of refugees themselves — as the reported drivers.
Surveillance data show reported measles cases from Tigray collapsed during the 2020–2022 war; afterward the median age of infection fell to five years and the odds a case was unvaccinated stayed sharply raised.
WHO and UNICEF estimates put DTP3 coverage at 85% for a second year running. Yellow fever protection sits at 53% in at-risk countries and HPV at 33% in girls, both far below target.
A WHO global update logged 79 human infections in the Americas and 16 confirmed cases in Africa by late May, with the virus surfacing in areas long considered free of it.
A national database of ~90% of public facilities found all-cause diarrhoea incidence in under-fives dropped 50% and hospitalisations 58% after 2020, with no rise in intussusception.
WHO reports 19,161 suspected cases and 166 deaths in a single month, most in children under five. The country had been close to eliminating the disease.
The objection turns on a no-treatment arm. WHO says placebo or no-treatment vaccine trials are acceptable only where no proven intervention exists, and here one does.
WHO and CDC estimate cases climbed about 20% in a single year, and the number of countries hit by large or disruptive outbreaks jumped from 36 to 57 — while global first-dose coverage stayed flat.
The year-end immunization summary reports 88% fewer measles deaths since 2000, malaria vaccine in 24 African countries, and 25 years without wild polio in the Western Pacific.
WHO has graded the regional resurgence a level 2 emergency. Only 5.7% of the 20,412 suspected cases were laboratory-confirmed, and the antitoxin that prevents most deaths is in global short supply.
A Global Burden of Disease analysis of 204 countries finds 15.7 million children received no DTP dose in 2023, more than half of them in eight countries, and only one of three target vaccines on track for 2030.
A Federal Register notice on 9 June listed eleven vaccine topics and ten scheduled votes over three days. An amended notice on 24 June listed seven topics, three votes and two days.
Two healthy children in Lae tested positive for cVDPV2 genetically linked to an Indonesian outbreak, in a country where coverage for a third oral polio dose was 44% in 2024.
The final analysis of a 28,130-child trial found roughly 78% efficacy over more than four years, evidence that underpins WHO's push to roll the conjugate vaccine out in endemic countries.